After the rejection of its last offer in December, Valeant Pharmaceuticals says that it has increased its offer for ISTA to $7.50 per share from $6.50 and adds that it has informed ISTA that the price could rise to $8.50 per share "assuming that ISTA provides it selected confirmatory due diligence related to the company that is consistent with what Valeant expects to … [Read more...] about Valeant increases offer for ISTA
News
MAP adds James O’Shea to board of directors
MAP Pharmaceuticals has appointed W. James O'Shea, a former President and COO of Sepracor, to its board of directors. During eight years at Sepracor, O'Shea held a number of positions in operations and commercialization and had previously worked for Zeneca Pharmaceuticals, including as Senior VP of Sales and Marketing and Medical Affairs. MAP is preparing for the … [Read more...] about MAP adds James O’Shea to board of directors
Respiratory drug delivery market projected to reach $44 billion by 2016
A new report available from BCC Research projects a compound annual growth rate (CAGR) of 14.3% for the respiratory drug delivery technologies market, meaning that the global market would approximately double to $44 billion by 2016. According to the report, the market, including MDIs, DPIs, and other devices, was $19.6 billion in 2010 would be about $22.5 billion for … [Read more...] about Respiratory drug delivery market projected to reach $44 billion by 2016
Vectura anticipates continued cuts in R&D expenditures
According to an interim management statement released by Vectura, the company anticipates a cut R&D expenditures by £1m for the fiscal year ending March 31 2012 and expects additional cuts for FY2013. The company said, "We continue to pay close attention to R&D expenditure to ensure appropriate investment is placed behind key assets, including device and product … [Read more...] about Vectura anticipates continued cuts in R&D expenditures
Fleming sells Ocean saline nasal spray to Valeant
Fleming Pharmaceuticals says that it sold the rights to its Ocean brand saline nasal products, along with three other products, to Valeant, which will distribute the product through Valeant Pharmaceuticals North America LLC. Ocean nasal sprays, irrigator, gel, and mist are available over the counter in the US. The company, which provides contract manufacturing of … [Read more...] about Fleming sells Ocean saline nasal spray to Valeant
Inverseon to focus on smoking cessation, COPD programs
California pharmaceutical company Inverseon has announced that it will redirect its development program for INV102, an inverse beta agonist, to focus on smoking cessation and COPD rather than asthma, although it is continuing to seek grants for development of the product as a treatment for asthma. Inverseon founder and Chair William Garner explained, “The … [Read more...] about Inverseon to focus on smoking cessation, COPD programs
Many patients with mild-to-moderate asthma may not respond to ICS
According to an article published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, only about a third of asthma patients not using an inhaled corticosteroid (ICS) and 17% of those using ICS had eosinophils in their sputum, an indicator of inflammation that suggests they would likely respond to ICS treatment. The … [Read more...] about Many patients with mild-to-moderate asthma may not respond to ICS
St Renatus gets funding for Phase 3 development of nasal spray dental anesthesia
An unnamed angel investment group is providing up to $3.5 million dollars to St. Renatus for Phase 3 clinical trials of its nasal mist dental anesthesia. St. Renatus announced in March 2011 that it had had a successful end-of-Phase 2 meeting with FDA regulators and planned to move ahead with Phase 3. The product, delivered to the nasal cavity, numbs only the upper … [Read more...] about St Renatus gets funding for Phase 3 development of nasal spray dental anesthesia
Wockhardt to launch generic fluticasone nasal spray in US
Mumbai-based pharmaceutical and biotechnology company Wockhardt says that it will launch its generic version of GSK's Flonase fluticasone nasal spray in the US immediately after having received approval from the US FDA. The company will manufacture the 50 mcg dose nasal spray for the treatment of allergic rhinitis at its facility in Morton Grove, IL. No other nasal … [Read more...] about Wockhardt to launch generic fluticasone nasal spray in US
GSK says “totality of the data” gives it confidence to submit applications for Relovair
GlaxoSmithKline and Theravance have announced the completion of Phase 3 studies of their Relovair fluticasone furoate/vilanterol DPI for COPD. One Phase 3 study for the treatment of asthma remains to be completed. Despite the fact that the studies failed to produce statistically significant improvements in a number of measures, GSK says that it will submit … [Read more...] about GSK says “totality of the data” gives it confidence to submit applications for Relovair